|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
3
|
|
pubmed:dateCreated |
2003-10-10
|
|
pubmed:abstractText |
Bisphosphonates (BP) are powerful inhibitors of bone resorption and are widely used in the treatment of patients with metastasis-induced osteolysis. In the present study, we show that a novel non-nitrogen-containing BP (BP7033) that exhibits antitumor activity is a potent inhibitor of both in vivo and in vitro angiogenesis. When administered to mice, BP7033 inhibited tumoral angiogenesis (65% at 0.06mg/injection) as well as tumor growth (65% at 0.006mg/injection) in a tumor model of A431 cells xenografted in nude mice, with no sign of toxicity. Additionally, in vivo angiogenesis induced by vascular endothelial growth factor-containing Matrigel implants was reduced by 90% in the presence of BP7033 (0.6mg/plug). In vitro, BP7033 inhibited proliferation of human umbilical vein endothelial cells (HUVEC) (IC(50) value 3x10(-4) M) and completely prevented the formation of capillary-like tubules by HUVEC in Matrigel. Moreover, treatment of A431 cells by BP7033 induced an inhibition of Ras processing and a decrease in the secretion of both vascular endothelial growth factor and matrix metalloproteinase-2, two well-known stimulators of the proliferation and migration of endothelial cells. These findings indicate that this new BP compound has marked antiangiogenic properties and thus represents a promising candidate for treatment of malignant diseases with an angiogenic component.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0006-291X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
24
|
|
pubmed:volume |
310
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
816-23
|
|
pubmed:dateRevised |
2006-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:14550277-Angiogenesis Inhibitors,
pubmed-meshheading:14550277-Animals,
pubmed-meshheading:14550277-Benzyl Alcohols,
pubmed-meshheading:14550277-Cell Division,
pubmed-meshheading:14550277-Cell Line, Tumor,
pubmed-meshheading:14550277-Cells, Cultured,
pubmed-meshheading:14550277-Collagen,
pubmed-meshheading:14550277-Diphosphonates,
pubmed-meshheading:14550277-Dose-Response Relationship, Drug,
pubmed-meshheading:14550277-Drug Combinations,
pubmed-meshheading:14550277-Endothelium, Vascular,
pubmed-meshheading:14550277-Female,
pubmed-meshheading:14550277-Humans,
pubmed-meshheading:14550277-Inhibitory Concentration 50,
pubmed-meshheading:14550277-Laminin,
pubmed-meshheading:14550277-Mice,
pubmed-meshheading:14550277-Mice, Nude,
pubmed-meshheading:14550277-Models, Chemical,
pubmed-meshheading:14550277-Neoplasm Transplantation,
pubmed-meshheading:14550277-Neoplasms,
pubmed-meshheading:14550277-Neovascularization, Pathologic,
pubmed-meshheading:14550277-Nitrogen,
pubmed-meshheading:14550277-Protein Processing, Post-Translational,
pubmed-meshheading:14550277-Proteoglycans,
pubmed-meshheading:14550277-Time Factors,
pubmed-meshheading:14550277-Umbilical Veins
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
A novel non-containing-nitrogen bisphosphonate inhibits both in vitro and in vivo angiogenesis.
|
|
pubmed:affiliation |
Laboratoire d'Oncologie Cellulaire et Moléculaire, UPRES 2360, Université Paris 13, UFR SMBH, Bobigny, France.
|
|
pubmed:publicationType |
Journal Article,
In Vitro,
Research Support, Non-U.S. Gov't
|
